Asthmatx Inc. executives undoubtedly felt pressure going into last month's hearing with the Food and Drug Administration's Anesthesiology and Respiratory Therapy Devices Panel, from which it sought a positive recommendation for its Alair bronchial thermoplasty system. Everything is at stake at these meetings: years of work; millions of venture capital dollars; the hopes and aspirations of employees who've toiled to develop a device to make sick people better. But the six-year-old start-up brought even more than the usual baggage to Rockville, MD. A negative recommendation from the panel might have been a serious blow to the interventional pulmonology industry that's been long on promise but short on results. (See "Devices Fill the Lung Space," START-UP, January 2006 Also see "Devices Fill The Lung Space " - Medtech Insight, 1 January, 2006..)
Nearly a year earlier, the same panel voted overwhelmingly, 13-2, to not recommend approval of Emphasys Medical's Zephyr bronchial valve,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
